Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis' SoloSTAR Lantus insulin pen marketed in US

Sanofi-aventis launches Lantus SoloSTAR, a disposable insulin pen, on the US market

Sanofi-aventis has launched its Lantus SoloSTAR, a disposable insulin pen, on the US market.

SoloSTAR pre-filled with Lantus (insulin glargine [rDNA origin]), the only 24-hour insulin approved exclusively for use once a day, for the treatment of hyperglycaemia in people with type 1 or type 2 diabetes.

The product is also the only prefilled disposable insulin pen which permits patients to administer doses from one to 80 units, in one injection and offers a 25 per cent greater maximum capacity than other insulin pens.

Equivalence studies have revealed that the product operates with a lower injection force and requires 31 per cent less injection force than the Novo Nordisk FlexPen and 54 per cent less force than the Eli Lilly Humulin/Humalog pen.

Lantus SoloSTAR is also available in Australia. Previously, it was introduced in France and Germany in 2007 and is expected to be introduced in other countries in the near future.

Angela Moskow, associate vice president of diabetes marketing at sanofi-aventis, said: "Insulin pens are underutilised in the US, compared with other countries, even though they may offer more convenience and flexibility for people with diabetes. Lantus SoloSTAR demonstrates sanofi-aventis' commitment to designing devices based on insights from people with diabetes, to help meet their lifestyle demands. We are excited to offer this new device."

30th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics